Study of ZG006 in Participants With Neuroendocrine Prostate Cancer

A Phase II Study Evaluating the Preliminary Efficacy and Safety of ZG006 in Participants With Metastatic Neuroendocrine Prostate Cancer

This is a multicenter, open-label Phase II study, aimed at exploring the preliminary efficacy and safety of ZG006 in patients with advanced metastatic NEPC who have previously failed standard treatment.

Inclusion Criteria:

• Male Participants aged 18 to 80 years (inclusive);
• Advanced metastatic neuroendocrine prostate cancer;
• disease progression after at least one line of platinum-based systemic therapy or intolerance to toxicity;
• Measurable disease according to RECIST v1.1 criteria;
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

Exclusion Criteria:

• Known positive test for human immunodeficiency virus (HIV) or hepatitis；
• Patients were deemed unsuitable for participating in the study by the investigator for any reason.